Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 6:34 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–3 of 3 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Locally Advanced or Metastatic Solid Tumors for Phase 1, Dose Escalation and Phase 2 Safety Lead-in, HNSCC for Phase 2 Dose Expansion, NSCLC for Phase 2 Dose Expansion
Interventions
Surzebiclimab, Tislelizumab, Alcestobart
Drug
Lead sponsor
BeiGene
Industry
Eligibility
18 Years and older
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
11
States / cities
Orange, California • Aurora, Colorado • Chicago, Illinois + 8 more
Conditions
Advanced Malignancies
Interventions
Tislelizumab, Pamiparib, Temozolomide, Sitravatinib, Ociperlimab, BAT1706, Fruquintinib, BGB-15025, Zanidatamab, BGB-A445, Surzebiclimab, Lenvatinib, LBL-007
Drug
Lead sponsor
BeOne Medicines
Industry
Eligibility
18 Years and older
Enrollment
404 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
4
States / cities
Miami, Florida • New York, New York • Nashville, Tennessee + 1 more
Conditions
Head and Neck Squamous Cell Carcinoma, Head and Neck Cancer
Interventions
Tislelizumab, BGB-A425, LBL-007
Drug
Lead sponsor
BeiGene
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
9
States / cities
Los Angeles, California • Stanford, California • Lone Tree, Colorado + 6 more